Jivolar

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to achieve glycaemic control when used with diet and exercise.

GNH USA supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Jivolar combines metformin and sitagliptin to improve glycaemic control in the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Adjunct to diet and exercise: enhances overall HbA1c reduction. - Combination with other antidiabetic agents: provides additional glucose‑lowering effect.

Jivolar may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Diarrhea: loose stools. - Upper abdominal pain: transient discomfort. - Headache: mild to moderate. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Hepatotoxicity: abnormal liver function tests. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before prescribing Jivolar, clinicians should consider several safety and handling factors.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic disease: monitor liver enzymes and use with caution. - Cardiovascular status: evaluate for heart failure risk. - Concomitant medications: review for drugs that may increase lactic acidosis risk. - Pregnancy and lactation: avoid use due to unknown safety profile. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Jivolar can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Alcohol: may potentiate lactic acidosis risk. - Iodinated contrast agents: can impair renal function, increasing metformin accumulation. - Cimetidine: may raise metformin plasma levels. - Nucleoside reverse transcriptase inhibitors: increase risk of lactic acidosis. - High‑dose corticosteroids: may affect glucose control.

Moderate Interactions (Monitor Closely): - Sulfonylureas: increased risk of hypoglycaemia. - Insulin: additive glucose‑lowering effect, monitor blood sugar. - Diuretics (thiazides): may raise blood glucose. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors: monitor renal function.